AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Television viewing
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Computer use
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Stress (adult)
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Adult sleep
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Child body mass index
Number of subjects: 813
Study 30336717 — intervention group
Group type: COMPARATOR
Intervention: Screen time (child)
Number of subjects: 813
Study 30336814 — intervention group
Group type: EXPERIMENTAL
Intervention: High post-PCI FFR (≥0.84)
Number of subjects: 621
Study 30336814 — intervention group
Group type: EXPERIMENTAL
Intervention: High %FFR increase (>15%)
Number of subjects: 621
Study 30336814 — intervention group
Group type: COMPARATOR
Intervention: Low post-PCI FFR (<0.84)
Number of subjects: 621
Study 30336814 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent FFR increase with PCI
Number of subjects: 621
Study 30336823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS
Number of subjects: 581
Study 30336823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 581
Study 30336823 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF-)IVUS
Number of subjects: 581
Study 30336828 — intervention group
Group type: EXPERIMENTAL
Intervention: Congo red staining of tenosynovial tissue
Number of subjects: 98
Study 30336828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac evaluation (biomarkers, electrocardiography, echocardiography with longitudinal strain, technetium pyrophosphate scintigraphy)
Number of subjects: 98
Study 30336828 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy initiation
Number of subjects: 98
Study 30336828 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TTR concentration and tetramer kinetic stability
Number of subjects: 98
Study 30336851 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock patients (n=29)
Number of subjects: 44
Study 30336851 — intervention group
Group type: COMPARATOR
Intervention: Septic patients (n=6)
Number of subjects: 44
Study 30336851 — intervention group
Group type: COMPARATOR
Intervention: Non-hospitalised subjects (n=9)
Number of subjects: 44
Study 30337280 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Mendelian randomization (MR) approach applied to genetic and biomarker data
Number of subjects: 4147
Study 30337300 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic mutations of the CCAAT/enhancer binding protein α
Number of subjects: 0
Study 30337314 — intervention group
Group type: COMPARATOR
Intervention: Healthy Newborns (HN)
Number of subjects: 167
Study 30337314 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns from pre-eclamptic women
Number of subjects: 167
Study 30337358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (≥0.1 mg/kg) in non-transfusion-dependent β-thalassemia
Number of subjects: 46
Study 30337358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (1.0 mg/kg) in transfusion-dependent β-thalassemia
Number of subjects: 46
Study 30338261 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Number of subjects: 0
Study 30338261 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 0
Study 30338311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapioca-based resistant starch type 4 (RS4) in a baked breakfast bar
Number of subjects: 21
Study 30338311 — intervention group
Group type: COMPARATOR
Intervention: Standard starch in a baked breakfast bar
Number of subjects: 21
Study 30338508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0
Study 30338508 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30338518 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block, suprascapular nerve block, and lateral sagittal infraclavicular brachial plexus block (LSIB)
Number of subjects: 23
Study 30338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to physician visits (defined as having at least two visits within 14 months after surgical resection)
Number of subjects: 241
Study 30338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to carcinoembryonic antigen (CEA) levels (defined as having at least four CEA levels drawn within 14 months)
Number of subjects: 241
Study 30338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to computed tomography (CT) (defined as completing CT between 10 and 14 months from surgical resection)
Number of subjects: 241
Study 30338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to colonoscopy (defined as completing colonoscopy between 10 and 14 months from surgical resection)
Number of subjects: 241
Study 30338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to postresection CRC guideline-recommended care
Number of subjects: 241
Study 30338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ankle-brachial index (ABI)
Number of subjects: 289
Study 30338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) and peripheral doppler ultrasound (DUS)
Number of subjects: 289
Study 30338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 289
Study 30338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery stenosis assessment
Number of subjects: 289
Study 30338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of asymptomatic patients with DM1
Number of subjects: 289
Study 30339323 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 689
Study 30339323 — intervention group
Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 689
Study 30339323 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity
Number of subjects: 689
Study 30339323 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels (low, moderate, high)
Number of subjects: 689
Study 30339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 30339775 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of children having half their plates filled with FV at dinner
Number of subjects: 160
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Child intake of FV
Number of subjects: 160
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Healthy Eating Index (HEI)
Number of subjects: 160
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child cooking skills and self-efficacy to cook healthy meals
Number of subjects: 160
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meal frequency
Number of subjects: 160
Study 30339784 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of more types of fruits and vegetables in the home
Number of subjects: 160
Study 30339892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tramadol and paracetamol
Number of subjects: 2144
Study 30339892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 2144
Study 30339892 — intervention group
Group type: EXPERIMENTAL
Intervention: PONV management guidance after discharge
Number of subjects: 2144
Study 30339892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated pain management written protocol
Number of subjects: 2144
Study 30339892 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised take-home analgesic and PONV strategies
Number of subjects: 2144
Study 30340199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5 mg, 10 mg, and 15 mg twice daily)
Number of subjects: 11
Study 30340460 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 243
Study 30340469 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNB using a 20-gauge ProCore needle
Number of subjects: 39
Study 30340532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary morphine (1 mg)
Number of subjects: 91
Study 30340532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 30340539 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE4-FL immunostaining in malignant nodules (n=17)
Number of subjects: 41
Study 30340539 — intervention group
Group type: COMPARATOR
Intervention: PACE4-FL immunostaining in benign nodules (n=24)
Number of subjects: 41
Study 30340539 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE4-altCT expression in malignant nodules (n=17)
Number of subjects: 41
Study 30340539 — intervention group
Group type: COMPARATOR
Intervention: Non-lesional thyroid parenchyma
Number of subjects: 41
Study 30340539 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity of high PACE4-FL immunostaining for malignancy
Number of subjects: 41
Study 30340583 — intervention group
Group type: EXPERIMENTAL
Intervention: BHOMA intervention
Number of subjects: 22
Study 30340583 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization Process Theory (NPT)
Number of subjects: 22
Study 30340648 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD self-management Action Plan intervention delivered by community health workers (CHWs) including COPD education, facilitated self-management Action Plans for COPD exacerbations, and monthly visits by CHWs.
Number of subjects: 240
Study 30340648 — intervention group
Group type: COMPARATOR
Intervention: COPD education and facilitated self-management Action Plans for COPD exacerbations.
Number of subjects: 240
Study 30340648 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures using EuroQol-5D (EQ-5D) and St. George's Respiratory Questionnaire (SGRQ) every 3 months over a period of 1 year.
Number of subjects: 240
Study 30340648 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of COPD Action Plans.
Number of subjects: 240
Study 30341043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1000
Study 30341043 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1000
Study 30341043 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly motivational emails during the treatment phase
Number of subjects: 1000
Study 30341050 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW intervention arm
Number of subjects: 300
Study 30341051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone intervention (smartphone app)
Number of subjects: 242
Study 30341051 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal coaching intervention (monthly calls with limited app components)
Number of subjects: 242
Study 30341052 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA TRACKER
Number of subjects: 200
Study 30341052 — intervention group
Group type: EXPERIMENTAL
Intervention: IDKmonitor
Number of subjects: 200
Study 30341052 — intervention group
Group type: EXPERIMENTAL
Intervention: Promonitor
Number of subjects: 200
Study 30341052 — intervention group
Group type: EXPERIMENTAL
Intervention: RIDASCREEN
Number of subjects: 200
Study 30341136 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria (asymptomatic)
Number of subjects: 240
Study 30341136 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria (symptomatic)
Number of subjects: 240
Study 30341136 — intervention group
Group type: COMPARATOR
Intervention: No malaria
Number of subjects: 240
Study 30341278 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-579-3p
Number of subjects: 0
Study 30341278 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A2
Number of subjects: 0
Study 30341664 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient insulin injection technique (IT)
Number of subjects: 52
Study 30341664 — intervention group
Group type: COMPARATOR
Intervention: Nurse insulin injection technique (IT)
Number of subjects: 52
Study 30341664 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient insulin injection technique (IT) score
Number of subjects: 52
Study 30341681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt excretion measurement
Number of subjects: 94
Study 30341681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sources of salt intake
Number of subjects: 94
Study 30341681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt addition at the table
Number of subjects: 94
Study 30341970 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 3733
Study 30341970 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 3733
Study 30342001 — intervention group
Group type: EXPERIMENTAL
Intervention: Gist Reasoning training
Number of subjects: 32
Study 30342001 — intervention group
Group type: COMPARATOR
Intervention: New Learning training
Number of subjects: 32
Study 30342029 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated polyp detection software (APDS)
Number of subjects: 55
Study 30342029 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists' detection
Number of subjects: 55
Study 30342495 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (RT)
Number of subjects: 94
Study 30342494 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 200
Study 30342494 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prediction model
Number of subjects: 200
Study 30342494 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored approach
Number of subjects: 200
Study 30342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of D7-cholesterol
Number of subjects: 2
Study 30343026 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP
Number of subjects: 3700
Study 30343070 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) and Cardiac Magnetic Resonance (CMR) with late gadolinium-enhancement (LGE)
Number of subjects: 38
Study 30343254 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX induction therapy
Number of subjects: 65
Study 30343526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (defined as serum 25(OH)D < 10 ng/mL) in ENKTL patients
Number of subjects: 251
Study 30343526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency in PTCL patients
Number of subjects: 251
Study 30343526 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in ENKTL patients
Number of subjects: 251
Study 30343526 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in PTCL patients
Number of subjects: 251
Study 30343526 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent validation cohort (n=115) for ENKTL
Number of subjects: 251
Study 30343614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for three cycles before radical cystectomy (RC)
Number of subjects: 50
Study 30343896 — intervention group
Group type: EXPERIMENTAL
Intervention: PLB-1001 (MET kinase inhibitor)
Number of subjects: 188
Study 30344012 — intervention group
Group type: COMPARATOR
Intervention: Progressive hemodialysis (HD) starting with one or two sessions per week, increasing frequency based on RRF decline.
Number of subjects: 152
Study 30344012 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group).
Number of subjects: 152
Study 30344036 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault injury group
Number of subjects: 511
Study 30344036 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 511
Study 30344036 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use disorder diagnosis
Number of subjects: 511
Study 30344036 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault injury at baseline
Number of subjects: 511
Study 30344036 — intervention group
Group type: EXPERIMENTAL
Intervention: Community violence exposure
Number of subjects: 511
Study 30344036 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 511
Study 30344063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Statins (both drugs)
Number of subjects: 1639
Study 30344063 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 1639
Study 30344063 — intervention group
Group type: COMPARATOR
Intervention: Statins only
Number of subjects: 1639
Study 30344063 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 1639
Study 30344179 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric co-management with proactive consultation for low-risk patients, co-management by geriatric nurse for high-risk patients, and additional medication review for patients with acute geriatric problems.
Number of subjects: 454
Study 30344179 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pre-cohort).
Number of subjects: 454
Study 30344197 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAD Study cohort
Number of subjects: 11423
Study 30344197 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigations and measurements in four domains (Lung, hEart, sociAl, boDy)
Number of subjects: 11423
Study 30344197 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up every four years
Number of subjects: 11423
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular signs or symptoms
Number of subjects: 696
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological signs
Number of subjects: 696
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized ocular pathology
Number of subjects: 696
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent systemic disease
Number of subjects: 696
Study 30345457 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment
Number of subjects: 0
Study 30345457 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 30345535 — intervention group
Group type: EXPERIMENTAL
Intervention: SEEG-guided RF-TC
Number of subjects: 296
Study 30346260 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stroke treatment
Number of subjects: 1662
Study 30346260 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 1662
Study 30346515 — intervention group
Group type: EXPERIMENTAL
Intervention: TAo-TAVI
Number of subjects: 253
Study 30346530 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led, games-based physical activity intervention
Number of subjects: 0
Study 30346530 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30346831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous reslizumab
Number of subjects: 321
Study 30347025 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 33
Study 30348076 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY syndrome individuals with ASD
Number of subjects: 64
Study 30348076 — intervention group
Group type: COMPARATOR
Intervention: XYY syndrome individuals (pre-natally diagnosed)
Number of subjects: 64
Study 30348076 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY syndrome individuals (overall)
Number of subjects: 64
Study 30348118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine
Number of subjects: 85
Study 30348127 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (docetaxel and cyclophosphamide, TC)
Number of subjects: 89
Study 30348127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 89
Study 30348216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Number of subjects: 53
Study 30348216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Pazopanib (800 mg/day)
Number of subjects: 53
Study 30348224 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 50
Study 30348537 — intervention group
Group type: EXPERIMENTAL
Intervention: DPYD genotype-guided dosing (initial dose reduction of 25% for c.2846A>T and c.1236G>A carriers, 50% for DPYD*2A and c.1679T>G carriers)
Number of subjects: 1103
Study 30348537 — intervention group
Group type: COMPARATOR
Intervention: Standard care (full dose fluoropyrimidine-based therapy)
Number of subjects: 1103
Study 30348537 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 1103
Study 30348537 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort (full dose fluoropyrimidine-based therapy)
Number of subjects: 1103
Study 30348538 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 268
Study 30348538 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 268
Study 30348618 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ALBI score
Number of subjects: 1434
Study 30348618 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ALBI score
Number of subjects: 1434
Study 30348618 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors evaluated in multivariate Cox regression analysis
Number of subjects: 1434
Study 30348638 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) combination therapy
Number of subjects: 43
Study 30349338 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPI
Number of subjects: 573
Study 30349338 — intervention group
Group type: COMPARATOR
Intervention: Armolipid Plus (AP)
Number of subjects: 573
Study 30349602 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30349736 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern family planning methods
Number of subjects: 46
Study 30349736 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning methods
Number of subjects: 46
Study 30349736 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling about family planning
Number of subjects: 46
Study 30349845 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 30